Related references
Note: Only part of the references are listed.Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+metastatic breast cancer progressing on trastuzumab therapy
J. O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Capecitabine vs. capecitabine plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05)
G. Von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Semisynthetic maytansine analogues for the targeted treatment of cancer
Wayne C. Widdison et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
The biogenesis of platelets from megakaryocyte propatelets
SR Patel et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
R Bruno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Drug-conjugated monoclonal antibodies for the treatment of cancer
JM Lambert
CURRENT OPINION IN PHARMACOLOGY (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Arming antibodies: prospects and challenges for immunoconjugates
AM Wu et al.
NATURE BIOTECHNOLOGY (2005)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study
AW Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
